Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05454735
Other study ID # 2021/616
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 10, 2022
Est. completion date December 1, 2023

Study information

Verified date July 2022
Source Centre Hospitalier Universitaire de Besancon
Contact Etienne CHAZAL, MD
Phone 0630244341
Email etienne.chazal@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

On-pump coronary artery bypass graft (CABG) and valve replacement surgeries are high-risk procedures. Among the risk factors for postoperative complications, perioperative hyperglycemia and blood glucose variability have been reported to be associated with increased morbidity and mortality. The treatment of hyperglycemia using intravenous insulin infusion improves the prognosis in cardiac surgery patients. However, the determinants of postoperative blood glucose variability and the mechanisms leading to its deleterious impact are unknown. Thus, to date, there is no therapeutic intervention that could effectively prevent and treat the deleterious impact of glycemic variability on postoperative outcome. The purpose of the study is to evaluate whether perioperative alteration of the autonomic nervous system and preoperative blood glucose variability could be related to perioperative glycemic variability.


Description:

The main objective is to describe the relationship between preoperative glycemic variability and glycemic variability during the first 48 postoperative hours. The secondary objectives are : 1. to describe the relationship between preoperative glycemic variability and glycemic variability during the first 48 hours postoperative according to: - diabetic and non-diabetic status - the type of surgical intervention 2. to describe the relationship between the parameters evaluating the preoperative activity of the autonomic nervous system and: - preoperative glycemic variability - glycemic variability during the first 48 postoperative hours 3. to describe the relationship between glycemic variability during the first 48 postoperative hours and: - parameters evaluating the activity of the autonomic nervous system during the first 48 postoperative hours - diabetes phenotype - markers of inflammation - markers of endothelial dysfunction 4. to describe the morbidity and mortality within 30 days after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Planned cardiac surgery - Age = 18 years old and < 80 years old - Group 1: patients with known insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass surgery - Group 2: patients with known non-insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass surgery - Group 3: non-diabetic patients undergoing planned aortic valve replacement surgery - Group 4: non-diabetic patients undergoing planned on-pump coronary artery bypass surgery Exclusion Criteria: - Emergent surgery (less than 48 hours between anesthestetic consultation and surgery) - Combined surgery (coronary artery bypass graft associated with valve surgery, multiple valve replacement, surgery of the ascending aorta) - Extreme weight: body mass index (BMI) > 35 kg.m-2 or < 18 kg.m-2. - Off-pump coronary artery bypass graft surgery - Type 1 diabetes mellitus - Patient unable to consent - Pregnant and/or breastfeeding woman - Permanent preoperative chronic heart rhythm disorder - Pacemaker - Unstable patient condition in preoperative period - Expected life expectancy less than 48 hours. - Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator. - Duration of continuous preoperative glycemic recording of less than 48 hours.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
coronary artery bypass surgery
coronary artery bypass surgery
aortic valve replacement surgery
aortic valve replacement surgery

Locations

Country Name City State
France Post operative intensive care unit of the cardiac surgery department Besançon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemic variability, measured by subcutaneous blood glucose continuous monitoring sensor, calculated by the coefficient of glycemic variability Continuous blood glucose monitoring using a subcutaneous blood glucose continuous monitoring sensor (FreeStyle Libre Pro) From 14 days before surgery (at least 48 hours before surgery) to 7 days after surgery
Secondary Autonomic nervous system activity, measured by non-invasive continuous heart rate monitoring, calculated by measuring the R-R interval Continuous non-invasive continuous heart rate monitoring using the MooKy HR memory device will allow the continuous measurement of the R-R interval and the R-R interval variability to quantify the activity of the autonomic nervous system. From the day before surgery (at admission in the cardiac surgery department the day before surgery) to Day 3 after surgery
Secondary Vasopressine blood level Vasopressine blood level will be measured from blood samples to assess the relationship between blood glucose variability and endothelial dysfunction. The day before surgery, at admission in the postoperative intensive care unit, at day 1 and at day 2 after surgery
Secondary Autonomic nervous system activity Compass 31 scale: the Compass 31 scale is a validated clinical scale that allows to identify the degree au autonomic nervous system dysfunction. The day before surgery.
Secondary Endocan blood level Endocan blood level will be measured from blood samples to assess the relationship between blood glucose variability and endothelial dysfunction. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
Secondary 8-iso PGF2a urinary level 8-iso PGF2a urinary level will be measured from urinary samples to assess the relationship between blood glucose variability and oxidative stress. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
Secondary IL-6 blood level IL-6 blood level will be measured from blood samples to assess the relationship between blood glucose variability and systemic inflammation. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
Secondary IL-10 blood level IL-10 blood level will be measured from blood samples to assess the relationship between blood glucose variability and systemic inflammation. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
Secondary TNF-alpha blood level TNF-alpha blood level will be measured from blood samples to assess the relationship between blood glucose variability and systemic inflammation. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
Secondary Angiotensine blood level Angiotensine blood level will be measured from blood samples to assess the relationship between blood glucose variability and endothelial dysfunction. The day before surgery, and at admission in the postoperative intensive care unit, and at day 1 and at day 2 after surgery.
See also
  Status Clinical Trial Phase
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT01184521 - Masimo CO-Oximeter Study Phase 0
Completed NCT05537168 - Bayesian Networks in Pediatric Cardiac Surgery
Completed NCT04269109 - Opioid Sparing Pain Management Strategy
Completed NCT05737147 - Comparison of the Accuracy and Precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature.
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Recruiting NCT02580292 - Diagnostic Accuracy of Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury .
Completed NCT02457572 - Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition N/A
Completed NCT00997217 - The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery Phase 1
Completed NCT01169441 - Lead Extract Study N/A
Completed NCT00336908 - Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery Phase 2/Phase 3
Terminated NCT05308589 - CPPF After General Cardiac Surgery N/A
Recruiting NCT03163238 - Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery Phase 2
Completed NCT02329158 - Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery
Completed NCT01029314 - Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass N/A
Completed NCT00459082 - A Pharmacokinetic Study of Dexmedetomine in Infants Phase 1
Completed NCT00122018 - An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery Phase 2
Terminated NCT03709693 - Clinical Outcomes in Patients Treated With SternaLock Blu
Completed NCT03976947 - Impact of Lung Recruitment Maneuvers on Driving Pressure in Cardiac Surgery
Completed NCT02398019 - Clinical Trial to Evaluate the Use of an Adsorption Membrane (oXiris®) During Cardiopulmonary Bypass Surgery N/A